Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A small but telling study finds that high levels of Ara h 6 — a peanut allergen protein — before starting oral immunotherapy (OIT) may flag patients at greater risk of quitting treatment due to reactions. Researchers also identified prior OIT failure as a key warning sign. Clinicians are urged to exercise extra caution when initiating peanut OIT in these higher-risk patients.
Knowing who might drop out of peanut oral immunotherapy (OIT) before treatment even begins could be a game-changer for allergists — and new research suggests a specific peanut protein may hold the answer. A study presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting found that elevated Ara h 6 levels prior to OIT, along with a history of prior OIT failure, were the strongest predictors of reaction-related treatment dropout.
Researchers at Boston Children's Hospital used machine learning to analyze 40 pre-OIT clinical characteristics — including demographics, atopic comorbidities, and baseline allergy testing — in 46 young patients (median age: 19 months). Ridge logistic regression emerged as the best-fit algorithm, identifying Ara h 6 and prior OIT failure as the top signals.
By the Numbers:
Why it matters: Most patients completed OIT successfully, but for the roughly 1 in 8 who didn't, reactions were the culprit. Identifying these patients upfront could help clinicians personalize dosing strategies, improve safety, and ultimately boost OIT success rates. The team plans to expand the cohort and explore salivary biomarkers as additional predictors.